ARS Pharmaceuticals, Inc (SPRY) financials · rev $84.3M
Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT
ARS Pharmaceuticals, Inc (SPRY) rev $84.3M.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $84.3M | $89.1M |
| Operating Income | -$179.4M | -$3.08M |
| Net Income | -$171.3M | $8.00M |
| EPS (Diluted) | -$1.74 | $0.08 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $327.7M | $351.2M |
| Current Assets | $284.9M | $334.3M |
| Cash & Equivalents | $41.3M | $50.8M |
| Inventory | $31.4M | $5.21M |
| PP&E | $2.46M | $1.03M |
| Total Liabilities | $213.4M | $94.4M |
| Current Liabilities | $39.1M | $23.4M |
| Long-term Debt | $96.4M | N/A |
| Total Debt | $96.4M† | N/A |
| Shareholders' Equity | $114.3M | $256.8M |
| Retained Earnings | -$294.6M | -$123.3M |
† Total Debt: Derived from long-term debt only (no total or short-term debt stored).
| Line | FY2025 | FY2024 |
|---|---|---|
| Operating Cash Flow | -$170.9M | $13.5M |
| CapEx | $339.0K | $563.0K |
| Investing Cash Flow | $56.8M | -$106.1M |
| Financing Cash Flow | $104.6M | $72.4M |
| Net Change in Cash | -$9.50M | -$20.2M |
| Free Cash Flow | -$171.2M | $13.0M |
FAQ
What is SPRY P/E and revenue?
ARS Pharmaceuticals, Inc (SPRY) rev $84.3M.
What is SPRY revenue?
ARS Pharmaceuticals, Inc last cached revenue is $84.3M (FY2025).
Is SPRY profitable?
ARS Pharmaceuticals, Inc last cached net income is -$171.3M (FY2025).
What are SPRY total assets?
ARS Pharmaceuticals, Inc last cached total assets are $327.7M (FY2025).
What is SPRY free cash flow?
ARS Pharmaceuticals, Inc last cached free cash flow is -$171.2M (FY2025).
Not investment advice. Cached statements, not a live tape.